PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis
| Autor: | Galina Selivanova, Jan Bergman, Vladimir J.N. Bykov, Helene Stridh, Nicole Zache, Jacob Westman, Klas G. Wiman |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cancer Research
Quinuclidines Lung Neoplasms Tumor suppressor gene Mutant Transplantation Heterologous Apoptosis Bone Neoplasms Mice SCID Biology Adenocarcinoma medicine.disease_cause Mice In vivo Carcinoma Non-Small-Cell Lung Genetics medicine Tumor Cells Cultured Neoplasm Animals Humans Drug Interactions Molecular Biology Cisplatin Aza Compounds Osteosarcoma medicine.disease Bridged Bicyclo Compounds Heterocyclic Genes p53 humanities Transplantation Drug Resistance Neoplasm Mutation Cancer research Carcinogenesis medicine.drug |
| Zdroj: | Oncogene. 24(21) |
| ISSN: | 0950-9232 |
| Popis: | Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|